869310-84-9

Usage

Uses

Used in Pharmaceutical Industry:
Tert-butyl (2-(2-(prop-2-yn-1-yloxy)ethoxy)ethyl)carbamate is used as a pharmaceutical intermediate for the synthesis of various drugs and active pharmaceutical ingredients. Its unique molecular structure allows for the development of new therapeutic agents with potential applications in treating a range of medical conditions.
Used in Agriculture:
In the agricultural sector, tert-butyl (2-(2-(prop-2-yn-1-yloxy)ethoxy)ethyl)carbamate is used as a chemical intermediate in the production of agrochemicals, such as pesticides and herbicides. Its specific properties may contribute to the development of more effective and targeted crop protection solutions.
Used in Materials Science:
Tert-butyl (2-(2-(prop-2-yn-1-yloxy)ethoxy)ethyl)carbamate may also find applications in the field of materials science, where it can be utilized as a component in the development of advanced materials with unique properties. Its incorporation into polymers, coatings, or other materials could lead to the creation of innovative products with improved performance characteristics.

Upstream product

• 139115-91-6 2-(2-tert-butyloxycarbonylaminoethoxy)ethanol 
• 106-96-7 propargyl bromide 
• 107-19-7 propargyl alcohol 
• 302331-20-0 methanesulfonic acid 2-(2-tert-butoxycarbonylamino-ethoxy)-ethyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 192132-77-7 2-(2-(tert-butoxycarbonylamino)ethoxy)ethyl 4-methylbenzenesulfonate 

Downstream Products

• 1271733-12-0 C₂₅H₄₁N₃O₆S 
• 944561-44-8 2-(2-(prop-2-yn-1-yloxy)ethoxy)ethan-1-amine 

Relevant academic research and scientific papers

MDM2 DEGRADERS AND USES THEREOF

The present invention relates to compounds and methods useful for the modulation of mouse double minute 2 homolog ("MDM2") protein via ubiquitination and/or degradation by compounds according to the present invention.

One-Step Synthesis of Photoaffinity Probes for Live-Cell MS-Based Proteomics

We present a one-step Ugi reaction protocol for the expedient synthesis of photoaffinity probes for live-cell MS-based proteomics. The reaction couples an amine affinity function with commonly used photoreactive groups, and a variety of handle functionalities. Using this technology, a series of pan-BET (BET: bromodomain and extra-terminal domain) selective bromodomain photoaffinity probes were obtained by parallel synthesis. Studies on the effects of photoreactive group, linker length and irradiation wavelength on photocrosslinking efficiency provide valuable insights into photoaffinity probe design. Optimal probes were progressed to MS-based proteomics to capture the BET family of proteins from live cells and reveal their potential on- and off-target profiles.

CGRP ANTAGONIST COMPOUNDS

The disclosures herein relate to novel compounds of Formula (1): and salts thereof, wherein A1, A2, Q, X, R1, R2 and R3 are defined herein, and their use in treating, preventing, ameliorating, control

Synthesis of oxygen-heterocycles having linker components for trapping cysteine derivatives

Tricyclic oxygen-heterocycles 10, 13a, 13b and 18 having a linker component were synthesized for the site-specific modification of proteins and peptides. The linker components were initially introduced by Sonogashira-Hagihara cross coupling of 5-bromo-2-hydroxybenzaldehyde 5 and a variety of alkynes. Next, the desired oxygen-heterocycles 10, 13a, 13b and 18 were synthesized by the condensation reaction of coupling products with cyclohexane-l,3-dione in the presence of N,N-diisopropylethylamine. Finally, the trapping ability of these oxygen-heterocycles was demonstrated by the representative reaction of oxygen-heterocycle 10 with glutathione 19 as a nucleophile having a thiol group.

Glycan-Gold Nanoparticles as Multifunctional Probes for Multivalent Lectin-Carbohydrate Binding: Implications for Blocking Virus Infection and Nanoparticle Assembly

Multivalent lectin-glycan interactions are widespread in biology and are often exploited by pathogens to bind and infect host cells. Glycoconjugates can block such interactions and thereby prevent infection. The inhibition potency strongly depends on matching the spatial arrangement between the multivalent binding partners. However, the structural details of some key lectins remain unknown and different lectins may exhibit overlapping glycan specificity. This makes it difficult to design a glycoconjugate that can potently and specifically target a particular multimeric lectin for therapeutic interventions, especially under the challenging in vivo conditions. Conventional techniques such as surface plasmon resonance (SPR) and isothermal titration calorimetry (ITC) can provide quantitative binding thermodynamics and kinetics. However, they cannot reveal key structural information, e.g., lectin's binding site orientation, binding mode, and interbinding site spacing, which are critical to design specific multivalent inhibitors. Herein we report that gold nanoparticles (GNPs) displaying a dense layer of simple glycans are powerful mechanistic probes for multivalent lectin-glycan interactions. They can not only quantify the GNP-glycan-lectin binding affinities via a new fluorescence quenching method, but also reveal drastically different affinity enhancing mechanisms between two closely related tetrameric lectins, DC-SIGN (simultaneous binding to one GNP) and DC-SIGNR (intercross-linking with multiple GNPs), via a combined hydrodynamic size and electron microscopy analysis. Moreover, a new term, potential of assembly formation (PAF), has been proposed to successfully predict the assembly outcomes based on the binding mode between GNP-glycans and lectins. Finally, the GNP-glycans can potently and completely inhibit DC-SIGN-mediated augmentation of Ebola virus glycoprotein-driven cell entry (with IC50 values down to 95 pM), but only partially block DC-SIGNR-mediated virus infection. Our results suggest that the ability of a glycoconjugate to simultaneously block all binding sites of a target lectin is key to robust inhibition of viral infection.

TRICYCLIC CRBN LIGANDS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of CRBN, and the treatment of CRBN-mediated disorders.

Novel camptothecin derivative, and preparation method and application thereof

The invention relates to a novel camptothecin derivative and application thereof, a tumor cell growth inhibitor, a ternary complex, and a method for improving the solubility of the camptothecin derivative. The camptothecin derivative is formed by modifying a substance represented by formula I through glycosylated triazole in the position R3. In a structural formula represented by the formula I, R1represents H, alkyl of C1-10, deuterated alkyl of the C1-10, or halogenated alkyl of the C1-10; R2 represents H, CH2N(CH3)2 or CH2N(CD3)2; R4 represents H, and X represents N, O or S; L represents polypeptide, C1-20 linear alkyl or a derivative thereof, a C1-20 linear or branched acyl derivative, or C2-100 ethylene glycol or a derivative thereof. The camptothecin derivative has high solubility, prepared anticancer drugs have the advantages of wide anticancer spectrum and high safety, and the in-vivo anticancer activity is superior to that of irinotecan hydrochloride.

Platinum-Triggered Bond-Cleavage of Pentynoyl Amide and N-Propargyl Handles for Drug-Activation

The ability to create ways to control drug activation at specific tissues while sparing healthy tissues remains a major challenge. The administration of exogenous target-specific triggers offers the potential for traceless release of active drugs on tumor sites from antibody-drug conjugates (ADCs) and caged prodrugs. We have developed a metal-mediated bond-cleavage reaction that uses platinum complexes [K2PtCl4 or Cisplatin (CisPt)] for drug activation. Key to the success of the reaction is a water-promoted activation process that triggers the reactivity of the platinum complexes. Under these conditions, the decaging of pentynoyl tertiary amides and N-propargyls occurs rapidly in aqueous systems. In cells, the protected analogues of cytotoxic drugs 5-fluorouracil (5-FU) and monomethyl auristatin E (MMAE) are partially activated by nontoxic amounts of platinum salts. Additionally, a noninternalizing ADC built with a pentynoyl traceless linker that features a tertiary amide protected MMAE was also decaged in the presence of platinum salts for extracellular drug release in cancer cells. Finally, CisPt-mediated prodrug activation of a propargyl derivative of 5-FU was shown in a colorectal zebrafish xenograft model that led to significant reductions in tumor size. Overall, our results reveal a new metal-based cleavable reaction that expands the application of platinum complexes beyond those in catalysis and cancer therapy.

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

A MedChem toolbox for cereblon-directed PROTACs

A modular chemistry toolbox was developed for cereblon-directed PROTACs. A variety of linkers was attached to a CRBN ligand via the 4-amino position of pomalidomide. We used linkers of different constitution to modulate physicochemical properties. We equipped one terminus of the linker with a set of functional groups, e.g. protected amines, protected carboxylic acids, alkynes, chloroalkanes, and protected alcohols, all of which are considered to be attractive for PROTAC design. We also highlight different opportunities for the expansion of the medicinal chemists' PROTAC toolbox towards heterobifunctional molecules, e.g. with biotin, fluorescent, hydrophobic and peptide tags.